Skip to content

Study · Measured the body's own peptide · 2026

2 results

Diagnostic potential of serum humanin in breast cancer among the Egyptian population.

Mohamed MH, Kamel WT, Ibrahim EH, Makboul A, Elemary AN, Mohammed DA

Discover oncology10 Jan 2026

PMID41518474 (opens in a new tab)PMCIDPMC12847494 (opens in a new tab)DOI10.1007/s12672-025-04325-x (opens in a new tab)PepBankPUB-41518474
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundGlobally, breast cancer is the most frequently diagnosed malignancy and the second leading cause of cancer-related mortality among women. The ongoing pursuit of early detection has driven interest in identifying and validating novel diagnostic biomarkers that could enhance prognosis and therapeutic outcomes. Humanin, a mitochondrial-derived peptide (MDP) with reported cytoprotective properties, has been implicated in cancer biology and may play a role in breast cancer pathogenesis.MethodsA total of 75 female patients with primary non-metastatic breast cancer and 70 age-matched healthy controls of comparable age were enrolled in this study. Serum concentrations of humanin were quantified using an enzyme-linked immunosorbent assay (ELISA).ResultsSerum humanin concentrations were significantly elevated in breast cancer patients compared with healthy controls (p < 0.001). Receiver operating characteristic (ROC) curve analysis demonstrated that humanin effectively differentiated breast cancer patients from controls, with a sensitivity of 78.7% and specificity of 62.9%.ConclusionThese findings suggest that humanin could serve as a promising biomarker for breast cancer screening and early detection. Further large-scale studies are warranted to validate its diagnostic potential and establish its clinical utility.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyEfficacy outcome

    In women with primary non-metastatic breast cancer, serum humanin concentrations were significantly higher than in healthy controls.

    In plain wordsWomen with breast cancer had higher natural humanin levels in their blood than healthy women.

    Peptide
    Humanin
    Outcome
    IncreaseSerum humanin in breast cancer versus controls
    Study

    n = 145

    Comparator
    Healthy controls
    Outcome group
    Aging markers · Cancer

    Source sentences

    Summary
    Serum humanin concentrations were significantly elevated in breast cancer patients compared with healthy controls (p < 0.001).
    2 context sentences
    Summary · context
    A total of 75 female patients with primary non-metastatic breast cancer and 70 age-matched healthy controls of comparable age were enrolled in this study.
    Summary · context
    Serum concentrations of humanin were quantified using an enzyme-linked immunosorbent assay (ELISA).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Serum humanin differentiated breast cancer patients from controls with a sensitivity of 78.7% and a specificity of 62.9%.

    In plain wordsNatural humanin levels in blood separated women with breast cancer from healthy women, with 78.7% sensitivity and 62.9% specificity.

    Peptide
    Humanin
    Outcome
    Not applicableDiagnostic accuracy of serum humanin (ROC analysis)
    Study

    n = 145

    Comparator
    Healthy controls
    Outcome group
    Aging markers · Cancer

    Measurements

    Sensitivity
    78.7%
    ROC analysis
    Specificity
    62.9%
    ROC analysis

    Source sentences

    Summary
    Receiver operating characteristic (ROC) curve analysis demonstrated that humanin effectively differentiated breast cancer patients from controls, with a sensitivity of 78.7% and specificity of 62.9%.
    2 context sentences
    Summary · context
    A total of 75 female patients with primary non-metastatic breast cancer and 70 age-matched healthy controls of comparable age were enrolled in this study.
    Summary · context
    Serum concentrations of humanin were quantified using an enzyme-linked immunosorbent assay (ELISA).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.